HONG KONG – Taiwan's National Health Insurance Administration has added Gilead Sciences Inc.'s Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide), a once-daily single tablet for the treatment of adults with HIV-1, to its list of reimbursed medicines.
HONG KONG – Taiwan's National Health Insurance Administration has added Gilead Sciences Inc.'s Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide), a once-daily single tablet for the treatment of adults with HIV-1, to its list of reimbursed medicines.
WASHINGTON – Since 2012, Americans at risk of HIV-1 infection from sex have had just a single option for reducing their odds of acquiring it: a daily dose of Gilead Sciences Inc.'s Truvada (emtricitabine and tenofovir disoproxil fumarate). Now, about a year before Truvada goes generic, at least some of them have a second option in Gilead's Descovy (emtricitabine and tenofovir alafenamide). On Thursday, the FDA approved Descovy for HIV-1 pre-exposure prophylaxis, or PrEP, to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex.
In a historic first, all prisoners and people covered through Medicaid in Louisiana got access last week to Asegua Therapeutics LLC's hepatitis C drug, even if they were in the early stages of the disease, thanks to a modified subscription program that's likely to serve as a model for other states in the U.S. looking for ways to pay for pricey cures and treatments emerging from the pipeline.
Durect Corp. (NASDAQ: DRXX) got a solid bump after announcing it granted Gilead Sciences Inc. exclusive worldwide rights to develop and commercialize a long-acting injectable HIV product created with Durect's platform, Saber, in a deal that could generate more than $300 million for Durect.
Kronos Bio Inc. closed a $105 million series A preferred stock financing, shored up by a board composed of longtime pharma executives that includes the company CEO and president, Norbert Bischofberger, the former Gilead Sciences Inc. R&D executive vice president and chief science officer.
DUBLIN – In what is a truly transformative deal for each company, Gilead Sciences Inc. and Galapagos NV are entering a 10-year research and development alliance under which Galapagos is getting $3.95 billion up front in hard cash plus another $1.1 billion in equity, in return for which Gilead will essentially have an option to ex-European rights on everything emanating from the Belgium firm's clinical and preclinical pipeline. That includes six clinical-stage programs, another 20 in preclinical research and whatever else Galapagos may bring forward – or bring in through its own business development efforts – over the term of the agreement.
Japanese biopharma Carna Biosciences Inc. and Gilead Sciences Inc., of Foster City, Calif., have signed a $470 million R&D collaboration to develop and commercialize small-molecule compounds in immuno-oncology. Under the agreement, Gilead will license worldwide rights to develop and commercialize inhibitors against an undisclosed immuno-oncology target from Kobe, Japan-based Carna. Additionally, Gilead will have access to Carna's lipid kinase drug discovery platform.
